IL6 and neoplasm: An abundance of evidence has established that IL-6 plays many roles in the tumor microenvironment, often as an immunosuppressive cytokine [41,42], and it is tempting to speculate that IL-6 secretion by cetuximab-resistant tumor cells could promote cetuximab resistance by downregulating cetuximab-induced ADCC.